# A First-in-human Single Ascending Dose/Multiple Ascending Dose Study of ENN0403 in Healthy Subjects

> **NCT05506540** · PHASE1 · COMPLETED · sponsor: **EnnovaBio** · enrollment: 69 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ENN0403 1mg
- **DRUG:** ENN0403 4mg
- **DRUG:** ENN0403 10mg
- **DRUG:** ENN0403 20mg
- **DRUG:** ENN0403 30mg
- **DRUG:** ENN0403 20mg (Fed)
- **DRUG:** ENN0403 6mg QD X 14 Days
- **DRUG:** ENN0403 12mg QD X 14 Days
- **DRUG:** ENN0403 20mg QD X 14 Days
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05506540
- **Lead sponsor:** EnnovaBio
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-17
- **Primary completion:** 2022-05-16
- **Final completion:** 2022-05-16
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05506540

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05506540, "A First-in-human Single Ascending Dose/Multiple Ascending Dose Study of ENN0403 in Healthy Subjects". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05506540. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*